25 XP   0   0   10

Canbridge Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Canbridge Pharmaceuticals Inc together

PenkeI guess you are interested in Canbridge Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Canbridge Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Canbridge Pharmaceuticals Inc

I send you an email if I find something interesting about Canbridge Pharmaceuticals Inc.

Quick analysis of Canbridge Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Canbridge Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
HK$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
HK$0.31
Expected worth in 1 year
HK$-0.99
How sure are you?
28.6%

+ What do you gain per year?

Total Gains per Share
HK$-1.30
Return On Investment
-302.3%

For what price can you sell your share?

Current Price per Share
HK$0.43
Expected price per share
HK$0.3 - HK$0.59
How sure are you?
50%

1. Valuation of Canbridge Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

HK$0.43

2. Growth of Canbridge Pharmaceuticals Inc (5 min.)




Is Canbridge Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$17m-$39.7m$73.8m216.8%

How much money is Canbridge Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$24.2m-$58.6m$34.3m141.5%
Net Profit Margin-345.6%-1,526.7%--

How much money comes from the company's main activities?

3. Financial Health of Canbridge Pharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#489 / 1007

Most Revenue
#295 / 1007

Most Profit
#918 / 1007

Most Efficient
#760 / 1007

What can you expect buying and holding a share of Canbridge Pharmaceuticals Inc? (5 min.)

Welcome investor! Canbridge Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Canbridge Pharmaceuticals Inc.

What can you expect buying and holding a share of Canbridge Pharmaceuticals Inc?

First you should know what it really means to hold a share of Canbridge Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Canbridge Pharmaceuticals Inc is HK$0.43. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Canbridge Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Canbridge Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is HK$0.31. Based on the TTM, the Book Value Change Per Share is HK$-0.33 per quarter. Based on the YOY, the Book Value Change Per Share is HK$2.18 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is HK$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Canbridge Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 HK$% of Price per ShareHK$% of Price per ShareHK$% of Price per ShareHK$% of Price per ShareHK$% of Price per Share
Usd Eps-0.03-7.6%-0.03-7.6%-0.10-22.9%-0.07-16.4%-0.05-11.7%
Usd Book Value Change Per Share-0.06-14.0%-0.04-9.7%0.2864.8%-0.15-33.8%-0.08-18.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.06-14.0%-0.04-9.7%0.2864.8%-0.15-33.8%-0.08-18.9%
Usd Price Per Share0.21-0.26-0.56-0.25-0.19-
Price to Earnings Ratio-1.59--1.98--1.45--1.03--0.74-
Price-to-Total Gains Ratio-3.46--4.16--3.56--3.86--3.01-
Price to Book Ratio5.19-3.63-2.76-1.92-1.38-
Price-to-Total Gains Ratio-3.46--4.16--3.56--3.86--3.01-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.054954
Number of shares18197
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.04-0.15
Usd Total Gains Per Share-0.04-0.15
Gains per Quarter (18197 shares)-755.83-2,645.64
Gains per Year (18197 shares)-3,023.32-10,582.57
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-3023-30330-10583-10593
20-6047-60560-21165-21176
30-9070-90790-31748-31759
40-12093-121020-42330-42342
50-15117-151250-52913-52925
60-18140-181480-63495-63508
70-21163-211710-74078-74091
80-24187-241940-84661-84674
90-27210-272170-95243-95257
100-30233-302400-105826-105840

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.03.00.00.0%0.010.00.00.0%0.010.00.00.0%0.010.04.00.0%3.010.012.012.0%
Book Value Change Per Share0.02.01.00.0%1.05.04.010.0%1.05.04.010.0%4.06.04.028.6%12.09.04.048.0%
Dividend per Share0.00.03.00.0%0.00.010.00.0%0.00.010.00.0%0.00.014.00.0%0.00.025.00.0%
Total Gains per Share0.02.01.00.0%1.05.04.010.0%1.05.04.010.0%4.06.04.028.6%12.09.04.048.0%

Fundamentals of Canbridge Pharmaceuticals Inc

About Canbridge Pharmaceuticals Inc

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, a glycosylation fusion protein that blocks the interaction between the CD95 receptor and its cognate ligand CD95L through binding to CD95L; CAN108, an orally administered small molecule ASBT inhibitor; CAN106, a recombinant human monoclonal antibody that specifically binds to and neutralizes C5 in the complement system; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN107, a fibroblast growth factor 23 (FGF23) blocking antibody; CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid. CANbridge Pharmaceuticals Inc. was founded in 2012 and is headquartered in Suzhou, China.

Fundamental data was last updated by Penke on 2024-04-19 09:06:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.

1.1. Profitability of Canbridge Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Canbridge Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Canbridge Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -506.8% means that $-5.07 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Canbridge Pharmaceuticals Inc:

  • The MRQ is -506.8%. The company is making a huge loss. -2
  • The TTM is -345.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-506.8%TTM-345.6%-161.2%
TTM-345.6%YOY-1,526.7%+1,181.2%
TTM-345.6%5Y-1,527.3%+1,181.7%
5Y-1,527.3%10Y-1,090.9%-436.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-506.8%-207.2%-299.6%
TTM-345.6%-218.5%-127.1%
YOY-1,526.7%-282.4%-1,244.3%
5Y-1,527.3%-432.2%-1,095.1%
10Y-1,090.9%-593.8%-497.1%
1.1.2. Return on Assets

Shows how efficient Canbridge Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Canbridge Pharmaceuticals Inc to the Biotechnology industry mean.
  • -35.5% Return on Assets means that Canbridge Pharmaceuticals Inc generated $-0.36 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Canbridge Pharmaceuticals Inc:

  • The MRQ is -35.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -27.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-35.5%TTM-27.3%-8.2%
TTM-27.3%YOY-56.6%+29.3%
TTM-27.3%5Y-44.4%+17.1%
5Y-44.4%10Y-31.7%-12.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-35.5%-13.2%-22.3%
TTM-27.3%-12.6%-14.7%
YOY-56.6%-11.5%-45.1%
5Y-44.4%-13.7%-30.7%
10Y-31.7%-15.5%-16.2%
1.1.3. Return on Equity

Shows how efficient Canbridge Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Canbridge Pharmaceuticals Inc to the Biotechnology industry mean.
  • -163.7% Return on Equity means Canbridge Pharmaceuticals Inc generated $-1.64 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Canbridge Pharmaceuticals Inc:

  • The MRQ is -163.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -89.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-163.7%TTM-89.8%-73.9%
TTM-89.8%YOY-50.7%-39.1%
TTM-89.8%5Y-43.2%-46.6%
5Y-43.2%10Y-30.9%-12.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-163.7%-16.7%-147.0%
TTM-89.8%-15.8%-74.0%
YOY-50.7%-14.4%-36.3%
5Y-43.2%-19.0%-24.2%
10Y-30.9%-19.9%-11.0%

1.2. Operating Efficiency of Canbridge Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Canbridge Pharmaceuticals Inc is operating .

  • Measures how much profit Canbridge Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Canbridge Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of -235.6% means the company generated $-2.36  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Canbridge Pharmaceuticals Inc:

  • The MRQ is -235.6%. The company is operating very inefficient. -2
  • The TTM is -78.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-235.6%TTM-78.5%-157.0%
TTM-78.5%YOY-254.3%+175.8%
TTM-78.5%5Y-389.7%+311.2%
5Y-389.7%10Y-278.3%-111.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-235.6%-286.5%+50.9%
TTM-78.5%-229.1%+150.6%
YOY-254.3%-288.4%+34.1%
5Y-389.7%-480.7%+91.0%
10Y-278.3%-624.7%+346.4%
1.2.2. Operating Ratio

Measures how efficient Canbridge Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.38 means that the operating costs are $0.38 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Canbridge Pharmaceuticals Inc:

  • The MRQ is 0.380. The company is very efficient in keeping operating costs low. +2
  • The TTM is 0.259. The company is very efficient in keeping operating costs low. +2
Trends
Current periodCompared to+/- 
MRQ0.380TTM0.259+0.122
TTM0.259YOY0.244+0.015
TTM0.2595Y0.238+0.021
5Y0.23810Y0.374-0.137
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3803.231-2.851
TTM0.2593.307-3.048
YOY0.2443.774-3.530
5Y0.2385.667-5.429
10Y0.3747.558-7.184

1.3. Liquidity of Canbridge Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Canbridge Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.04 means the company has $1.04 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Canbridge Pharmaceuticals Inc:

  • The MRQ is 1.036. The company is just able to pay all its short-term debts.
  • The TTM is 1.296. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.036TTM1.296-0.260
TTM1.296YOY3.929-2.633
TTM1.2965Y3.128-1.832
5Y3.12810Y2.235+0.894
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0363.890-2.854
TTM1.2964.182-2.886
YOY3.9295.343-1.414
5Y3.1286.135-3.007
10Y2.2356.453-4.218
1.3.2. Quick Ratio

Measures if Canbridge Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Canbridge Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 0.08 means the company can pay off $0.08 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Canbridge Pharmaceuticals Inc:

  • The MRQ is 0.080. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.076. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.080TTM0.076+0.004
TTM0.076YOY2.904-2.828
TTM0.0765Y1.408-1.332
5Y1.40810Y1.289+0.120
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0803.528-3.448
TTM0.0764.059-3.983
YOY2.9045.390-2.486
5Y1.4086.138-4.730
10Y1.2896.488-5.199

1.4. Solvency of Canbridge Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Canbridge Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Canbridge Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.78 means that Canbridge Pharmaceuticals Inc assets are financed with 78.3% credit (debt) and the remaining percentage (100% - 78.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Canbridge Pharmaceuticals Inc:

  • The MRQ is 0.783. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.635. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.783TTM0.635+0.148
TTM0.635YOY1.789-1.154
TTM0.6355Y2.016-1.381
5Y2.01610Y1.493+0.523
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7830.339+0.444
TTM0.6350.337+0.298
YOY1.7890.273+1.516
5Y2.0160.368+1.648
10Y1.4930.391+1.102
1.4.2. Debt to Equity Ratio

Measures if Canbridge Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Canbridge Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 361.0% means that company has $3.61 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Canbridge Pharmaceuticals Inc:

  • The MRQ is 3.610. The company is unable to pay all its debts with equity. -1
  • The TTM is 2.053. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ3.610TTM2.053+1.556
TTM2.053YOY0.525+1.529
TTM2.0535Y0.855+1.199
5Y0.85510Y0.684+0.170
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.6100.388+3.222
TTM2.0530.403+1.650
YOY0.5250.342+0.183
5Y0.8550.432+0.423
10Y0.6840.461+0.223

2. Market Valuation of Canbridge Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Canbridge Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Canbridge Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -1.59 means the investor is paying $-1.59 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Canbridge Pharmaceuticals Inc:

  • The EOD is -0.418. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.586. Based on the earnings, the company is expensive. -2
  • The TTM is -1.978. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.418MRQ-1.586+1.168
MRQ-1.586TTM-1.978+0.392
TTM-1.978YOY-1.452-0.527
TTM-1.9785Y-1.029-0.949
5Y-1.02910Y-0.735-0.294
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.418-2.249+1.831
MRQ-1.586-2.553+0.967
TTM-1.978-2.669+0.691
YOY-1.452-4.107+2.655
5Y-1.029-6.247+5.218
10Y-0.735-6.499+5.764
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Canbridge Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--3.288+3.288
TTM--3.552+3.552
YOY--5.560+5.560
5Y--8.326+8.326
10Y--8.881+8.881
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Canbridge Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.19 means the investor is paying $5.19 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Canbridge Pharmaceuticals Inc:

  • The EOD is 1.370. Based on the equity, the company is underpriced. +1
  • The MRQ is 5.192. Based on the equity, the company is overpriced. -1
  • The TTM is 3.629. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD1.370MRQ5.192-3.822
MRQ5.192TTM3.629+1.563
TTM3.629YOY2.764+0.865
TTM3.6295Y1.918+1.711
5Y1.91810Y1.379+0.539
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.3701.929-0.559
MRQ5.1922.090+3.102
TTM3.6292.091+1.538
YOY2.7642.881-0.117
5Y1.9183.545-1.627
10Y1.3793.936-2.557
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Canbridge Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.471-0.325-31%2.180-122%-1.138+142%-0.637+35%
Book Value Per Share--0.3140.628-50%-0.733+333%-0.276+188%2.883-89%
Current Ratio--1.0361.296-20%3.929-74%3.128-67%2.235-54%
Debt To Asset Ratio--0.7830.635+23%1.789-56%2.016-61%1.493-48%
Debt To Equity Ratio--3.6102.053+76%0.525+588%0.855+322%0.684+427%
Dividend Per Share----0%-0%-0%-0%
Eps---0.257-0.2570%-0.771+200%-0.552+115%-0.394+53%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.714+40%
Market Cap182544453.120-279%691970833.920863194700.800-20%1860821363.200-63%817204819.200-15%622531166.537+11%
Net Profit Margin---5.068-3.456-32%-15.267+201%-15.273+201%-10.909+115%
Operating Margin---2.356-0.785-67%-2.543+8%-3.897+65%-2.783+18%
Operating Ratio--0.3800.259+47%0.244+56%0.238+60%0.374+2%
Pb Ratio1.370-279%5.1923.629+43%2.764+88%1.918+171%1.379+277%
Pe Ratio-0.418+74%-1.586-1.978+25%-1.452-8%-1.029-35%-0.735-54%
Price Per Share0.430-279%1.6302.033-20%4.383-63%1.925-15%1.466+11%
Price To Free Cash Flow Ratio----0%-0%-0%-0%
Price To Total Gains Ratio-0.913+74%-3.462-4.161+20%-3.562+3%-3.861+12%-3.015-13%
Quick Ratio--0.0800.076+5%2.904-97%1.408-94%1.289-94%
Return On Assets---0.355-0.273-23%-0.566+59%-0.444+25%-0.317-11%
Return On Equity---1.637-0.898-45%-0.507-69%-0.432-74%-0.309-81%
Total Gains Per Share---0.471-0.325-31%2.180-122%-1.138+142%-0.637+35%
Usd Book Value--17033087.85634061806.166-50%-39767559.202+333%-14959494.552+188%156410274.100-89%
Usd Book Value Change Per Share---0.060-0.042-31%0.279-122%-0.145+142%-0.081+35%
Usd Book Value Per Share--0.0400.080-50%-0.094+333%-0.035+188%0.368-89%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.033-0.0330%-0.099+200%-0.071+115%-0.050+53%
Usd Free Cash Flow----0%-0%-0%-0%
Usd Market Cap23329181.109-279%88433872.575110316282.762-20%237812970.217-63%104438775.894-15%79559483.083+11%
Usd Price Per Share0.055-279%0.2080.260-20%0.560-63%0.246-15%0.187+11%
Usd Profit---27880975.800-24298963.995-13%-58678036.601+110%-44407648.393+59%-31719748.852+14%
Usd Revenue--5501917.8003718767.000+48%2287492.200+141%2086616.160+164%5521274.9360%
Usd Total Gains Per Share---0.060-0.042-31%0.279-122%-0.145+142%-0.081+35%
 EOD+3 -4MRQTTM+4 -21YOY+14 -135Y+18 -910Y+15 -13

3.2. Fundamental Score

Let's check the fundamental score of Canbridge Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.418
Price to Book Ratio (EOD)Between0-11.370
Net Profit Margin (MRQ)Greater than0-5.068
Operating Margin (MRQ)Greater than0-2.356
Quick Ratio (MRQ)Greater than10.080
Current Ratio (MRQ)Greater than11.036
Debt to Asset Ratio (MRQ)Less than10.783
Debt to Equity Ratio (MRQ)Less than13.610
Return on Equity (MRQ)Greater than0.15-1.637
Return on Assets (MRQ)Greater than0.05-0.355
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Canbridge Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.500
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in CNY. All numbers in thousands.

Summary
Total Assets569,047
Total Liabilities445,606
Total Stockholder Equity123,441
 As reported
Total Liabilities 445,606
Total Stockholder Equity+ 123,441
Total Assets = 569,047

Assets

Total Assets569,047
Total Current Assets342,253
Long-term Assets226,794
Total Current Assets
Cash And Cash Equivalents 271,160
Net Receivables 26,387
Inventory 19,883
Other Current Assets 12,425
Total Current Assets  (as reported)342,253
Total Current Assets  (calculated)329,855
+/- 12,398
Long-term Assets
Property Plant Equipment 141,679
Other Assets 1,730
Long-term Assets  (as reported)226,794
Long-term Assets  (calculated)143,409
+/- 83,385

Liabilities & Shareholders' Equity

Total Current Liabilities330,475
Long-term Liabilities115,131
Total Stockholder Equity123,441
Total Current Liabilities
Short Long Term Debt 26,873
Accounts payable 172,234
Other Current Liabilities 121,557
Total Current Liabilities  (as reported)330,475
Total Current Liabilities  (calculated)320,664
+/- 9,811
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt117,067
Long-term Liabilities  (as reported)115,131
Long-term Liabilities  (calculated)117,067
+/- 1,936
Total Stockholder Equity
Common Stock28
Other Stockholders Equity 278,960
Total Stockholder Equity (as reported)123,441
Total Stockholder Equity (calculated)278,988
+/- 155,547
Other
Capital Stock28
Common Stock Shares Outstanding 424,393
Net Invested Capital 158,189
Net Tangible Assets 40,056
Net Working Capital 11,778
Property Plant and Equipment Gross 141,679



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-06-302023-03-312022-12-312022-06-302021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302015-06-302014-12-312014-06-302013-12-312013-06-302012-12-312012-06-302011-12-312011-06-302010-12-312010-06-302009-12-312009-06-302008-12-312008-06-302007-12-312007-06-302006-12-312006-06-302005-12-312005-06-302004-12-312004-06-302003-12-312003-06-302002-12-312002-06-302001-12-312001-06-30
> Total Assets 
168,555
243,099
292,392
321,093
349,213
396,084
445,036
513,816
552,944
600,019
577,735
583,803
730,665
4,481,099
4,676,900
4,122,151
4,664,659
4,106,880
3,882,766
3,990,311
4,046,110
3,505,248
3,486,339
3,702,178
3,968,241
3,970,575
5,738,396
5,610,830
5,676,344
0
586,358
0
551,371
0
892,522
842,450
702,045
0
569,047
569,0470702,045842,450892,5220551,3710586,35805,676,3445,610,8305,738,3963,970,5753,968,2413,702,1783,486,3393,505,2484,046,1103,990,3113,882,7664,106,8804,664,6594,122,1514,676,9004,481,099730,665583,803577,735600,019552,944513,816445,036396,084349,213321,093292,392243,099168,555
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
391,045
391,045
427,191
480,432
811,711
811,711
654,119
505,160
342,253
342,253
342,253342,253505,160654,119811,711811,711480,432427,191391,045391,04500000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
360,804
0
442,100
0
745,815
604,616
451,157
0
271,160
271,1600451,157604,616745,8150442,1000360,804000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
318,785
0
0
0
0
0000318,7850000000000000000000000000000000000
       Net Receivables 
46,426
54,902
59,410
43,097
63,486
82,593
97,485
117,118
113,103
104,753
105,667
136,425
104,579
103,949
162,909
432,974
413,753
0
962
39,788
50
36,221
3,541
53,182
145,735
330,821
547,875
795,136
1,018,576
25,005
25,005
14,806
17,294
9,141
9,141
14,553
19,054
26,387
26,387
26,38726,38719,05414,5539,1419,14117,29414,80625,00525,0051,018,576795,136547,875330,821145,73553,1823,54136,2215039,7889620413,753432,974162,909103,949104,579136,425105,667104,753113,103117,11897,48582,59363,48643,09759,41054,90246,426
       Other Current Assets 
0
0
0
0
0
0
0
0
0
313
313
266
157,982
140,755
135,293
75,525
163,469
352,187
99,682
11,323
73,254
19,870
89,740
132,518
103,316
97,900
202,051
68,464
69,430
4,683
4,683
1,991
19,769
43,307
43,307
0
0
12,425
12,425
12,42512,4250043,30743,30719,7691,9914,6834,68369,43068,464202,05197,900103,316132,51889,74019,87073,25411,32399,682352,187163,46975,525135,293140,755157,982266313313000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
195,313
0
70,939
0
80,811
188,331
196,885
0
226,794
226,7940196,885188,33180,811070,9390195,313000000000000000000000000000000
       Property Plant Equipment 
52,940
86,582
93,349
102,940
124,020
152,849
186,920
213,401
210,539
228,277
231,170
214,596
211,480
3,903,965
4,109,388
3,411,171
3,732,151
3,656,171
3,678,576
3,779,330
3,859,641
3,359,428
3,319,558
3,432,550
3,486,679
3,446,781
3,359,229
3,322,227
3,314,627
15,570
15,570
15,541
16,089
29,542
29,542
131,339
144,717
141,679
141,679
141,679141,679144,717131,33929,54229,54216,08915,54115,57015,5703,314,6273,322,2273,359,2293,446,7813,486,6793,432,5503,319,5583,359,4283,859,6413,779,3303,678,5763,656,1713,732,1513,411,1714,109,3883,903,965211,480214,596231,170228,277210,539213,401186,920152,849124,020102,94093,34986,58252,940
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
25,715
27,279
0
0
0
0
0
0
0
0
0
0
0
12,201
0
0
0
0
0
0
0
0
0
0
0
0
00000000000012,2010000000000027,27925,7150000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
25,715
27,279
0
0
0
0
59,790
0
0
72,113
0
0
0
1,550,127
1,239,000
1,187,740
0
179,743
0
54,850
0
51,269
50,185
68,133
0
0
0068,13350,18551,269054,8500179,74301,187,7401,239,0001,550,12700072,1130059,790000027,27925,7150000000000000
       Other Assets 
0
0
0
0
0
0
0
0
24,476
24,672
24,618
22,832
23,273
75,530
80,057
51,413
51,372
24,939
24,847
59,790
60,426
73,678
72,113
72,643
74,442
58,439
1,607,837
1,294,469
1,242,305
0
0
0
0
0
0
6,807
0
1,730
1,730
1,7301,73006,8070000001,242,3051,294,4691,607,83758,43974,44272,64372,11373,67860,42659,79024,84724,93951,37251,41380,05775,53023,27322,83224,61824,67224,47600000000
> Total Liabilities 
95,596
99,333
121,796
124,891
139,444
153,130
168,867
188,306
213,148
242,077
213,247
179,805
171,116
1,544,452
1,539,730
788,596
759,600
319,692
88,551
50,849
38,263
43,254
86,367
189,489
336,275
378,954
1,494,564
1,089,218
1,079,917
0
2,332,214
0
2,616,169
0
199,131
335,645
393,490
0
445,606
445,6060393,490335,645199,13102,616,16902,332,21401,079,9171,089,2181,494,564378,954336,275189,48986,36743,25438,26350,84988,551319,692759,600788,5961,539,7301,544,452171,116179,805213,247242,077213,148188,306168,867153,130139,444124,891121,79699,33395,596
   > Total Current Liabilities 
91,737
94,981
117,747
124,476
139,132
152,969
155,490
150,806
188,148
192,077
179,914
163,138
171,116
361,206
417,125
788,596
759,600
319,692
88,551
50,849
38,263
43,254
46,367
189,489
336,275
378,954
1,042,111
706,468
709,982
108,103
108,103
118,155
100,925
185,780
185,780
214,645
278,105
330,475
330,475
330,475330,475278,105214,645185,780185,780100,925118,155108,103108,103709,982706,4681,042,111378,954336,275189,48946,36743,25438,26350,84988,551319,692759,600788,596417,125361,206171,116163,138179,914192,077188,148150,806155,490152,969139,132124,476117,74794,98191,737
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
22,314
0
14,066
0
30,868
29,904
26,867
0
26,873
26,873026,86729,90430,868014,066022,314000000000000000000000000000000
       Accounts payable 
48,749
46,928
61,419
49,801
74,244
82,276
63,860
68,398
81,176
67,257
53,969
56,196
55,311
59,580
50,711
43,481
35,433
207
209
215
220
226
223
37,331
41,473
118,564
55,966
42,787
43,335
46,713
46,713
60,013
42,108
43,607
43,607
108,307
107,540
172,234
172,234
172,234172,234107,540108,30743,60743,60742,10860,01346,71346,71343,33542,78755,966118,56441,47337,33122322622021520920735,43343,48150,71159,58055,31156,19653,96967,25781,17668,39863,86082,27674,24449,80161,41946,92848,749
       Other Current Liabilities 
29,809
8,208
41,692
18,400
64,625
70,417
80,028
69,733
90,261
74,484
83,966
73,609
64,779
235,039
220,061
228,370
678,311
319,332
87,432
49,289
36,447
40,250
44,222
151,421
293,265
260,390
436,145
311,681
364,647
13,692
13,692
14,878
21,192
103,423
103,423
0
0
121,557
121,557
121,557121,55700103,423103,42321,19214,87813,69213,692364,647311,681436,145260,390293,265151,42144,22240,25036,44749,28987,432319,332678,311228,370220,061235,03964,77973,60983,96674,48490,26169,73380,02870,41764,62518,40041,6928,20829,809
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,224,111
0
2,515,244
0
13,351
121,000
115,385
0
115,131
115,1310115,385121,00013,35102,515,24402,224,111000000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,351
121,000
0
0
0
000121,00013,3510000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
37,928
37,928
29,768
101
0
0
0
0
0
0
00000010129,76837,92837,92800000000000000000000000000000
> Total Stockholder Equity
72,959
143,766
170,596
196,202
209,769
242,954
276,169
325,510
339,796
357,942
364,488
403,998
559,549
1,862,068
1,995,423
2,536,581
2,992,681
3,787,188
3,794,215
3,939,462
4,008,521
3,464,876
3,402,906
3,531,925
3,647,743
3,610,727
3,696,320
4,096,847
4,191,509
0
-1,745,856
0
-2,064,798
0
693,391
506,805
308,555
0
123,441
123,4410308,555506,805693,3910-2,064,7980-1,745,85604,191,5094,096,8473,696,3203,610,7273,647,7433,531,9253,402,9063,464,8764,008,5213,939,4623,794,2153,787,1882,992,6812,536,5811,995,4231,862,068559,549403,998364,488357,942339,796325,510276,169242,954209,769196,202170,596143,76672,959
   Common Stock
200
4,800
14,400
14,400
14,400
14,400
14,400
14,400
14,400
14,400
14,400
23,040
27,812
176,299
176,762
234,523
276,290
289,290
361,290
362,886
401,907
419,616
419,616
585,451
654,031
673,031
743,631
803,211
818,521
5
5
5
5
28
28
28
0
28
28
282802828285555818,521803,211743,631673,031654,031585,451419,616419,616401,907362,886361,290289,290276,290234,523176,762176,29927,81223,04014,40014,40014,40014,40014,40014,40014,40014,40014,4004,800200
   Retained Earnings 
69,748
85,014
121,026
135,215
160,302
174,358
224,853
273,481
286,556
293,357
300,127
266,142
282,062
663,054
599,074
764,717
993,838
1,375,004
1,438,594
1,532,293
1,501,316
1,006,120
954,219
873,744
848,328
611,867
589,074
0
0
-1,850,124
-1,850,124
-1,962,487
-2,194,327
0
-2,858,211
-3,087,145
0
-3,628,766
-3,628,766
-3,628,766-3,628,7660-3,087,145-2,858,2110-2,194,327-1,962,487-1,850,124-1,850,12400589,074611,867848,328873,744954,2191,006,1201,501,3161,532,2931,438,5941,375,004993,838764,717599,074663,054282,062266,142300,127293,357286,556273,481224,853174,358160,302135,215121,02685,01469,748
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,461,026
3,461,026
0
0
0
0003,461,0263,461,0260000000000000000000000000000000000
   Treasury Stock000000000000000000-12800000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
94,682
94,682
82,663
119,943
693,363
693,363
132,896
0
278,960
278,960
278,960278,9600132,896693,363693,363119,94382,66394,68294,68200000000000000000000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in HKD. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue78,972
Cost of Revenue-30,078
Gross Profit48,89448,894
 
Operating Income (+$)
Gross Profit48,894
Operating Expense-528,487
Operating Income-476,612-479,593
 
Operating Expense (+$)
Research Development311,174
Selling General Administrative195,689
Selling And Marketing Expenses-
Operating Expense528,487506,863
 
Net Interest Income (+$)
Interest Income6,863
Interest Expense-3,893
Other Finance Cost-5,940
Net Interest Income-2,970
 
Pretax Income (+$)
Operating Income-476,612
Net Interest Income-2,970
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-483,475-476,612
EBIT - interestExpense = -3,893
-483,475
-479,582
Interest Expense3,893
Earnings Before Interest and Taxes (EBIT)--479,582
Earnings Before Interest and Taxes (EBITDA)-454,634
 
After tax Income (+$)
Income Before Tax-483,475
Tax Provision-0
Net Income From Continuing Ops-483,475-483,475
Net Income-483,475
Net Income Applicable To Common Shares-483,475
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-2,970
 

Technical Analysis of Canbridge Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Canbridge Pharmaceuticals Inc. The general trend of Canbridge Pharmaceuticals Inc is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Canbridge Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Canbridge Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.5 < 0.5 < 0.59.

The bearish price targets are: 0.32 > 0.3 > 0.3.

Tweet this
Canbridge Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Canbridge Pharmaceuticals Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Canbridge Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Canbridge Pharmaceuticals Inc.

Canbridge Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartCanbridge Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Canbridge Pharmaceuticals Inc. The current adx is .

Canbridge Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Canbridge Pharmaceuticals Inc.

Canbridge Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Canbridge Pharmaceuticals Inc.

Canbridge Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartCanbridge Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Canbridge Pharmaceuticals Inc.

Canbridge Pharmaceuticals Inc Daily Stochastic Oscillator ChartCanbridge Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Canbridge Pharmaceuticals Inc.

Canbridge Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartCanbridge Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Canbridge Pharmaceuticals Inc.

Canbridge Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartCanbridge Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Canbridge Pharmaceuticals Inc.

Canbridge Pharmaceuticals Inc Daily Williams %R ChartCanbridge Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Canbridge Pharmaceuticals Inc.

Canbridge Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Canbridge Pharmaceuticals Inc.

Canbridge Pharmaceuticals Inc Daily Average True Range (ATR) ChartCanbridge Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Canbridge Pharmaceuticals Inc.

Canbridge Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartCanbridge Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Canbridge Pharmaceuticals Inc.

Canbridge Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartCanbridge Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Canbridge Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-23BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-29BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-20MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-21MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-25RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-29ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Canbridge Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Canbridge Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.500
Total1/1 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Canbridge Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Canbridge Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Canbridge Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Canbridge Pharmaceuticals Inc

I send you an email if I find something interesting about Canbridge Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Canbridge Pharmaceuticals Inc.

Receive notifications about Canbridge Pharmaceuticals Inc in your mailbox!